Boehringer Ingelheim to invest €65 million in avian vaccines

Lyon, France, 11 April 2018 - Six months after inaugurating its new French animal health headquarters in the heart of the Lyon-Gerland Biodistrict, Boehringer Ingelheim has confirmed its allegiance to the region by announcing that it is about to invest a further €65 million in the metropolitan area.

The German group has laid the first stone of a 5,700 sq m building at its Lyon Porte-des-Alpes (LPA) site. Known as F2IVE (Formulation and Filling of Inactivated Vaccines Extension), this major project will comprise a three-storey building - including 1,000 sq m of clean room space – mainly for formulating and distributing avian vaccines.

“As poultry consumption continues to rise around the world, there is an increasing demand for avian vaccines. This meant that our LPA production site in Saint-Priest was going to reach a saturation point by 2020. We had to do some forward planning and find additional production capacity”, explains Erick Lelouche, President of Boehringer Ingelheim Animal Health France.

The new building, which has an environmentally friendly design, will house two formulation lines, a multi-format bottle distribution line and a bag distribution area.

42 new jobs to be created at the new site

Earthworks for the new high-tech building began in March 2018 with the first batches expected in spring 2020 for a range of avian vaccines destined for the world market, with the exception of the US.

Fifteen months after the acquisition of Merial (a Sanofi company) in January 2017, this new investment will lead to the creation of 42 new jobs, primarily consisting of qualified operations staff (flow and maintenance managers, production technicians).

“An investment such as this confirms the commitment made by Boehringer Ingelheim at the time of the acquisition to put France, and Lyon in particular, at the heart of its growth strategy in the animal health market”, Erick Lelouche shares. 

Over the past 22 years, more than €350 million have been invested in the LPA site. This new investment will eventually result in a threefold increase in the site’s inactivated vaccine production capacity.

About Boehringer Ingelheim

Innovative medicines for people and animals have for more than 130 years been what the research-driven pharmaceutical company Boehringer Ingelheim stands for. Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies and to this day remains family-owned. Day by day, some 50,000 employees create value through innovation for the three business areas human pharmaceuticals, animal health and biopharmaceutical contract manufacturing. In 2016, Boehringer Ingelheim achieved net sales of around 15.9 billion euros. With more than three billion euros, R&D expenditure corresponds to 19.6 per cent of net sales.

Social responsibility comes naturally to Boehringer Ingelheim. That is why the company is involved in social projects such as the “Making More Health” initiative. Boehringer Ingelheim also actively promotes workforce diversity and benefits from its employees’ different experiences and skills. Furthermore, the focus is on environmental protection and sustainability in everything the company does.

More information about Boehringer Ingelheim can be found on www.boehringer-ingelheim.com or in our annual report: http://annualreport.boehringer-ingelheim.com(link is external)

About Boehringer Ingelheim Animal Health

As the second largest animal health business in the world, Boehringer Ingelheim is committed to improving animal health. With more than 10,000 employees worldwide, Boehringer Ingelheim Animal Health has products available in more than 150 markets and a global presence in 99 countries. For more information about Boehringer Ingelheim Animal Health, click here.